• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同时期糖尿病视网膜病变进展的速率:系统评价和荟萃分析。

Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis.

机构信息

Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.

出版信息

Diabetes Care. 2009 Dec;32(12):2307-13. doi: 10.2337/dc09-0615.

DOI:10.2337/dc09-0615
PMID:19940227
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2782996/
Abstract

OBJECTIVE

This meta-analysis reviews rates of progression of diabetic retinopathy to proliferative diabetic retinopathy (PDR) and/or severe visual loss (SVL) and temporal trends.

RESEARCH DESIGN AND METHODS

This systematic literature review and meta-analysis of prospective studies assesses progression of retinopathy among diabetic patients without treatment for retinopathy at baseline. Studies published between 1975 to February 2008 were identified. Outcomes of interest were rates of progression to PDR and/or SVL. Pooled baseline characteristics and outcome measures were summarized using weighted averages of counts and means. Baseline characteristics and outcomes were compared between two periods: 1975-1985 and 1986-2008.

RESULTS

A total of 28 studies comprising 27,120 diabetic patients (mean age 49.8 years) were included. After 4 years, pooled incidence rates for PDR and SVL were 11.0 and 7.2%, respectively. Rates were lower among participants in 1986-2008 than in 1975-1985. After 10 years, similar patterns were observed. Participants in 1986-2008 studies had lower proportions of PDR and non-PDR at all time points than participants in 1975-1985 studies.

CONCLUSIONS

Since 1985, diabetic patients have lower rates of progression to PDR and SVL. These findings may reflect an increased awareness of retinopathy risk factors; earlier identification and initiation of care for patients with retinopathy; and improved medical management of glucose, blood pressure, and serum lipids. Differences in baseline characteristics, particularly in the prevalence and severity of retinopathy, could also have contributed to these temporal differences.

摘要

目的

本荟萃分析回顾了糖尿病性视网膜病变进展为增殖性糖尿病性视网膜病变(PDR)和/或严重视力丧失(SVL)的比率和时间趋势。

研究设计与方法

本系统文献回顾和前瞻性研究的荟萃分析评估了基线时未接受视网膜病变治疗的糖尿病患者的视网膜病变进展情况。确定了 1975 年至 2008 年 2 月期间发表的研究。关注的结局是进展为 PDR 和/或 SVL 的发生率。使用计数和均值的加权平均值总结了汇总的基线特征和结局指标。比较了两个时期的基线特征和结局:1975-1985 年和 1986-2008 年。

结果

共纳入了 28 项研究,涉及 27120 名糖尿病患者(平均年龄 49.8 岁)。4 年后,PDR 和 SVL 的累积发生率分别为 11.0%和 7.2%。1986-2008 年期间的发生率低于 1975-1985 年期间。10 年后,观察到类似的模式。与 1975-1985 年研究相比,1986-2008 年研究的参与者在所有时间点的 PDR 和非 PDR 比例均较低。

结论

自 1985 年以来,糖尿病患者进展为 PDR 和 SVL 的比率较低。这些发现可能反映了对视网膜病变危险因素的认识提高;对视网膜病变患者的早期识别和治疗;以及对血糖、血压和血清脂质的更有效的医疗管理。基线特征的差异,特别是视网膜病变的患病率和严重程度的差异,也可能促成了这些时间差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb5/2782996/00d231047c52/zdc0120979110001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb5/2782996/00d231047c52/zdc0120979110001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb5/2782996/00d231047c52/zdc0120979110001.jpg

相似文献

1
Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis.不同时期糖尿病视网膜病变进展的速率:系统评价和荟萃分析。
Diabetes Care. 2009 Dec;32(12):2307-13. doi: 10.2337/dc09-0615.
2
Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States.美国不同严重程度的糖尿病视网膜病变与视力相关的功能负担
JAMA Ophthalmol. 2017 Sep 1;135(9):926-932. doi: 10.1001/jamaophthalmol.2017.2553.
3
Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.玻璃体内注射 0.19mg 氟轻松醋酸酯植入物对糖尿病视网膜病变进展和消退的长期影响。
Ophthalmology. 2017 Apr;124(4):440-449. doi: 10.1016/j.ophtha.2016.11.034. Epub 2017 Jan 9.
4
Prevalence and incidence of visual impairment in patients with proliferative diabetic retinopathy in India.印度增生性糖尿病视网膜病变患者视力障碍的患病率和发病率。
Sci Rep. 2020 Jun 29;10(1):10513. doi: 10.1038/s41598-020-67350-6.
5
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内雷珠单抗治疗增生性糖尿病视网膜病变的 5 年疗效比较:一项随机临床试验。
JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148. doi: 10.1001/jamaophthalmol.2018.3255.
6
How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy.糖尿病视网膜病变进展的多少个阶段是有意义的?威斯康星糖尿病视网膜病变流行病学研究。
Arch Ophthalmol. 2001 Apr;119(4):547-53. doi: 10.1001/archopht.119.4.547.
7
The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes.视网膜病变的出现及向增殖性视网膜病变的进展:世界卫生组织糖尿病血管疾病多国研究
Diabetologia. 2001 Sep;44 Suppl 2:S22-30. doi: 10.1007/pl00002935.
8
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group: Report 3: Baseline Retinopathy and Clinical Features Predict Progression of Diabetic Retinopathy.英国糖尿病视网膜病变电子病历用户组:报告3:基线视网膜病变及临床特征预测糖尿病视网膜病变的进展
Am J Ophthalmol. 2017 Aug;180:64-71. doi: 10.1016/j.ajo.2017.05.020. Epub 2017 May 29.
9
Diabetic Retinopathy in Patients with Dyslipidemia: Development and Progression.血脂异常患者的糖尿病视网膜病变:发生与进展
Ophthalmol Retina. 2018 Jan;2(1):38-45. doi: 10.1016/j.oret.2017.05.010. Epub 2017 Aug 9.
10
Six year incidence and progression of diabetic retinopathy: results from the Mauritius diabetes complication study.糖尿病视网膜病变的六年发病率及病情进展:毛里求斯糖尿病并发症研究结果
Diabetes Res Clin Pract. 2006 Sep;73(3):298-303. doi: 10.1016/j.diabres.2006.02.009. Epub 2006 Apr 3.

引用本文的文献

1
Diabetic retinal disease.糖尿病视网膜病变
Nat Rev Dis Primers. 2025 Aug 28;11(1):62. doi: 10.1038/s41572-025-00646-x.
2
Evaluating diabetic retinopathy service utilisation amongst Cardiology Department admissions.评估心脏病科住院患者中糖尿病视网膜病变的服务利用情况。
Ir J Med Sci. 2025 Jul 23. doi: 10.1007/s11845-025-04010-6.
3
Genetic mechanisms of hemispheric functional connectivity in diabetic retinopathy: a joint neuroimaging and transcriptomic study.糖尿病视网膜病变中半球功能连接的遗传机制:一项神经影像学与转录组学联合研究

本文引用的文献

1
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.坎地沙坦对2型糖尿病视网膜病变进展和逆转的影响(DIRECT-Protect 2):一项随机安慰剂对照试验。
Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411-7. Epub 2008 Sep 25.
2
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.坎地沙坦对1型糖尿病视网膜病变预防(DIRECT-Prevent 1)和进展(DIRECT-Protect 1)的作用:随机、安慰剂对照试验。
Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25.
3
Front Cell Dev Biol. 2025 May 6;13:1590627. doi: 10.3389/fcell.2025.1590627. eCollection 2025.
4
The evolution of diabetic retinopathy screening.糖尿病视网膜病变筛查的演变
Eye (Lond). 2025 Apr;39(6):1040-1046. doi: 10.1038/s41433-025-03633-4. Epub 2025 Feb 5.
5
Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: a pooled cohort's analysis.二甲双胍和磺脲类药物单独或联合治疗的持续时间对新诊断2型糖尿病患者糖尿病视网膜病变的影响:一项汇总队列分析
Int J Retina Vitreous. 2025 Jan 31;11(1):9. doi: 10.1186/s40942-025-00637-w.
6
The application of artificial intelligence in diabetic retinopathy: progress and prospects.人工智能在糖尿病视网膜病变中的应用:进展与展望。
Front Cell Dev Biol. 2024 Oct 25;12:1473176. doi: 10.3389/fcell.2024.1473176. eCollection 2024.
7
The Diabetic Retinopathy "Pandemic" and Evolving Global Strategies: The 2023 Friedenwald Lecture.糖尿病视网膜病变“大流行”与不断演变的全球策略:2023年弗里登瓦尔德讲座
Invest Ophthalmol Vis Sci. 2023 Dec 1;64(15):47. doi: 10.1167/iovs.64.15.47.
8
Surgical strategy and outcome in patients with bilateral proliferative diabetic retinopathy.双侧增殖性糖尿病视网膜病变患者的手术策略与预后
Int Ophthalmol. 2023 Dec;43(12):4921-4931. doi: 10.1007/s10792-023-02895-9. Epub 2023 Oct 14.
9
Diabetic microaneurysms detected by fluorescein angiography spatially correlate with regions of macular ischemia delineated by optical coherence tomography angiography.荧光素眼底血管造影术检测到的糖尿病性微动脉瘤与光学相干断层扫描血管造影术描绘的黄斑缺血区域在空间上相关。
Indian J Ophthalmol. 2023 Aug;71(8):3085-3090. doi: 10.4103/IJO.IJO_3155_22.
10
'I don`t need an eye check-up'. A qualitative study using a behavioural model to understand treatment-seeking behaviour of patients with sight threatening diabetic retinopathy (STDR) in India.“我不需要眼部检查”。一项使用行为模型理解印度威胁视力的糖尿病视网膜病变(STDR)患者寻求治疗行为的定性研究。
PLoS One. 2023 Jun 15;18(6):e0270562. doi: 10.1371/journal.pone.0270562. eCollection 2023.
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium.
美国国立眼科研究所/美国食品药品监督管理局眼科临床试验设计与终点研讨会报告。
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):479-89. doi: 10.1167/iovs.07-1132.
4
Management of diabetic retinopathy: a systematic review.糖尿病视网膜病变的管理:一项系统评价。
JAMA. 2007 Aug 22;298(8):902-16. doi: 10.1001/jama.298.8.902.
5
Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.鲁比前列酮对糖尿病性黄斑水肿患者的影响:PKC-DMES随机临床试验的30个月结果
Arch Ophthalmol. 2007 Mar;125(3):318-24. doi: 10.1001/archopht.125.3.318.
6
The relationships between risk factors and the distribution of retinopathy lesions in type 2 diabetes.2型糖尿病中危险因素与视网膜病变病变分布之间的关系。
Acta Ophthalmol Scand. 2006 Oct;84(5):619-23. doi: 10.1111/j.1600-0420.2006.00710.x.
7
Prevention and early detection of vascular complications of diabetes.糖尿病血管并发症的预防与早期检测
BMJ. 2006 Sep 2;333(7566):475-80. doi: 10.1136/bmj.38922.650521.80.
8
Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Linköping Diabetes Complications Study.1型糖尿病非选择性人群中严重视网膜病变发病率的下降及肾病的持续减少——林雪平糖尿病并发症研究
Diabetologia. 2004 Jul;47(7):1266-1272. doi: 10.1007/s00125-004-1431-6. Epub 2004 Jul 2.
9
Important causes of visual impairment in the world today.当今世界视力损害的重要原因。
JAMA. 2003 Oct 15;290(15):2057-60. doi: 10.1001/jama.290.15.2057.
10
Lifetime risk for diabetes mellitus in the United States.美国糖尿病的终生风险。
JAMA. 2003 Oct 8;290(14):1884-90. doi: 10.1001/jama.290.14.1884.